5-BPDi Stats & Data

5-BPDi (Indanyl-α-PHP) is a hexanone pyrrolidinophenone first detected on the grey market circa mid-2010s; formal human pharmacology/toxicology is lacking. As with related pyrrolidinophenones (α-PVP/MDPV), strong dopaminergic/noradrenergic stimulation can cause marked tachycardia, hypertension, anxiety, bruxism, vasoconstriction (cold/numb extremities), and hypervigilance; plan a dose cap, avoid heat/exertion, and monitor pulse/BP if possible. Residual stimulation often outlasts euphoria—late redosing commonly leads to insomnia and paranoia; set a hard stop time and prepare sleep hygiene or non-alcoholic sedating measures (without mixing high doses of depressants). Avoid combining with other stimulants or MAOIs due to hypertensive crisis/arrhythmia risk; tramadol and bupropion increase seizure risk; decongestants increase vasoconstriction. Because cathinone powders are frequently mis-sold/adulterated, use lab drug checking where available or multiple reagents (Marquis, Froehde, Simon’s, Zimmermann, Morris) and start with a 0.5–1 mg allergy test; expect that names/labels may not match contents. Oral administration is safer than insufflation; if snorting, reduce tissue damage and infection risk by using sterile personal equipment, crushing finely, rinsing with sterile saline, and spacing lines. Maintain hydration with electrolytes (about 250 mL/h at rest up to ~500 mL/h if active) without overhydrating; eat before use and plan a recovery window with sleep. Avoid use if you have cardiovascular disease, severe anxiety/psychosis risk, or during pregnancy/breastfeeding. Seek urgent care for chest pain, severe headache, confusion, hyperthermia, seizures, or prolonged psychosis—these can reflect stimulant toxicity or excited delirium.